BridgeBio Pharma, Inc.

Approval AI-extracted

acoramidis

transthyretin amyloid cardiomyopathy (ATTR-CM)

Resolved

64days ago

Approval decision · May 4, 2026

What's at stake A final FDA approval decision on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) is expected May 4, 2026.

Primary source · SEC 8-K verified 16h ago

“On May 4, 2026, the Brazilian Health Regulatory Agency (ANVISA) approved BEYONTTRA™ (acoramidis) for use in adult patients with ATTR-CM in Brazil.”